- Global Model
- About Us
- Contact Us
Loading the content... Loading depends on your connection speed!
Including: Lung-on-chip, Heart-on-chip, Liver-on-chip, Intestine-on-chip, Kidney-on-chip and Human-on-chip, Human disease and tissue models, and Microfluidics.
Historic and Forecast 2010 – 2020
Covering: North America, Europe, Rest Of World (ROW)
This report covers OOCs manufactured by university spinoffs and others. It includes both organ models which are designed on typical chip-like structures and organ models which are designed on microfluidic micrometric plates.
Organ-on-chip or organ-on-a-chip (OOCs) are microfluidic 3D cell culture devices that closely mimic the key physiological functions of body organs. These chips are usually transparent, flexible and about the size of a computer memory stick. An OOC is also referred to as a biomimetic microsystem or 3D microphysiologic platform or human disease and tissue models.
OOCs are one of the most exciting multidisciplinary areas of scientific research. They have the distinguishing characteristic of emulating the human micro environment in vitro, which is not possible by any other conventional in-vitro techniques. This unique feature of an OOC is the result of integrating biology with technology.
Scientific advances in cell biology, microfabrication and microfluidics have led to the development of OOCs. They are tiny chip-like structures with specific embedded cells. The combination of chip and cells in the presence of suitable conditions mimic the key functions of an organ in miniature formats outside the body.
Scientific advances in cell biology, microfabrication and microfluidics have led to the development of Organ-on-Chips (OOCs). OOCs are microfluidic 3D cell culture devices that closely mimic the key physiological functions of body organs. Microchips are not designed to biomimic an entire organ, but simulate the physiology of a single functional unit of an organ system.
These microchips are one of the most exciting areas of scientific research as they have the distinguishing characteristic of emulating the human micro environment in vitro. This unique feature of OOCs is made possible by integrating biology with advanced engineering technologies.
OOCs have potential applications in many major industries including pharmaceutical, agriculture, agrochemicals, chemicals, consumer goods, cosmetics, food and beverages and nutraceuticals, as well as for research. Currently the pharmaceutical industry is dominant in leveraging this technology. The immediate need in the pharmaceutical industry for OOCs is in preclinical testing of drugs. The technology also shows significant potential for drug screening and lead optimization and in fact for use in every aspect of drug discovery and development. Other important potential healthcare applications of OOCs include disease modelling, patient stratification, phenotypic screening and personalized health.
OOC technology is still in an initial stage. The players in the market are basically university spinoffs involved in the commercialization of OOC prototypes developed in the universities. They are few in number. The key players include Emulate, CN-Bio, Mimetas, TissUse, Hurel and Nortis. Currently OOCs are marketed primarily through sales agreements with end users that involve collaboration of both parties in tailoring the OOCs to meet the end user’s requirements.
The global market for OOC devices was valued at $XX million in 2015 and is expected to grow at a rapid compound annual growth rate (CAGR) of XX% to 2020. Up to 2018 the OOC market is expected to rise at this high CAGR due to an increase in number of collaborative sales agreements between the pharmaceutical companies and university spin-offs and the entry of new advanced models of OOC devices into the market. The anticipated launch of humans-on-chips in 2018 will further increase the growth rate from 2018.
Further improvements in the design and manufacture of OOCs will probably replace animal models as subjects in preclinical drug evaluations in future. Overall, they have the potential to break an impasse in in-vitro drug discovery and development.
Organ-on-Chip, Lung-on-chip, Heart-on-chip, Liver-on-chip, Intestine-on-chip, Kidney-on-chip and Human-on-chip, Human disease and tissue models, and Microfluidics.
CN Bio Innovations, Emulate Inc., TissUse GmbH, Mimetas, HµREL Corporation (HµREL), Nortis, InSphero, Tara Biosystems, and AxoSim Techologies LLC
North America, Europe and Rest Of World(ROW)
Historic and Forecast 2010 to 2020
Market volume in $ Million
|SOURCING AND REFERENCING||
Data and analysis throughout the report is sourced using end notes.